查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999327

骶髂關節融合市場：2026-2032年全球市場預測（依產品類型、手術方法、入路、固定機制、銷售管道及最終用戶分類）

Sacroiliac Joint Fusion Market by Product Type, Procedure Type, Approach, Fixation Mechanism, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，骶髂關節融合市場價值將達到 8.4842 億美元，到 2026 年將成長至 9.4286 億美元，到 2032 年將達到 19.1034 億美元，年複合成長率為 12.29%。

主要市場統計數據
基準年 2025 8.4842億美元
預計年份：2026年 9.4286億美元
預測年份：2032年 1,910,340,000 美元
複合年成長率 (%) 12.29%

在不斷發展的醫療環境中，骶髂關節融合手術的現狀和臨床需求影響著器械的開發、患者的治療途徑以及醫療保健提供者的決策。

隨著臨床醫生尋求持久且微創的解決方案來治療頑固性骶髂關節功能障礙，骶髂關節融合術在脊椎和骨盆治療中佔據越來越重要的地位。隨著先進影像技術、標靶注射和多學科評估融入診斷流程，患者選擇標準變得更加嚴格，明確了手術指徵。同時，醫療設備研發人員和臨床醫生致力於降低組織創傷，提高動態穩定性，同時兼顧鄰近解剖結構和長期融合的生物機制。

新技術和變革性護理模式正在迅速改變骶髂關節融合手術的技術、設備設計和臨床實施模式。

骶髂關節融合術正經歷一場變革，主要得益於植入材料、術中導航和手術物流的創新。影像和導航技術的進步降低了許多醫療團隊對透視的依賴，從而縮短了學習曲線，並提高了手術室運作。導航輔助的微創技術能夠實現更精準的植入，可望降低併發症發生率，並使更多患者能夠接受手術。同時，植入形態和表面技術的改進，以及更豐富的材料選擇，促使設計者致力於最佳化初始固定和長期融合的生物學特性。

評估 2025 年美國關稅變化將如何影響所有利害關係人的供應鏈、採購重點、定價策略和業務永續營運。

2025年實施的一系列關稅調整為醫療設備相關人員的採購和供應鏈策略引入了新的變數。從海外採購零件和成品的製造商正在重新評估其供應商所在地，以降低進口關稅風險，這加速了關於近岸外包和雙重採購的討論。這些調整正在影響前置作業時間和庫存策略，促使醫院、門診手術中心和專科診所評估緩衝策略和合約柔軟性，以維持醫療服務的連續性。

以細分市場為中心的分析揭示了每種產品類型、治療方法、最終用戶、途徑、固定機制和銷售管道的不同需求徵兆。

以細分市場為重點的分析揭示了產品、手術流程、最終用戶、手術入路、固定機制和銷售管道等不同維度上的需求模式和發展重點。按產品類型分類，此細分市場區分植入和手術器械，尤其關注植入的材料選擇。在植入，PEEK籠式結構與鈦籠式結構展開競爭，兩者在放射學和動態方面各有優勢，影響著外科醫師的選擇。依手術類型分類，手術方式多種多樣，涵蓋微創手術到開放性手術。微創手術的特點在於採用透視引導流程和導航支援平台，而開放性手術則通常依賴手術技巧和既定的手術暴露策略。

影響全球採用率、報銷管道、臨床基礎設施和商業化策略的區域趨勢和患者人口統計。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的採納選擇、監管重點和商業化管道均有顯著影響。在美洲，成熟的臨床路徑和高密度的先進脊椎中心促進了微創技術和先進植入的快速普及。同時，醫院網路結構和門診手術中心的成長也影響採購週期和採購談判。在歐洲和中東及非洲，法規結構和報銷體系的多樣性導致採納時間存在差異。一些市場優先考慮集中採購和成本效益分析，而另一些市場則優先考慮透過私人醫院系統快速獲取新型醫療設備。

對醫療設備製造商和服務供應商的競爭格局進行分析，重點在於策略舉措、產品創新、夥伴關係關係、市場進入方式以及能力差距。

骶髂關節融合領域企業的策略主要圍繞著三大主題：差異化的臨床價值、一體化服務交付和可擴展性。一些企業強調強大的臨床證據和明確的手術優勢，並將研發重點放在最佳化植入設計和手術器械的人體工學上，以縮短手術時間和降低併發症風險。同時，其他企業則致力於開發整合系統，將導航、植入和服務合約捆綁在一起，以降低手術團隊和醫療機構採用該系統的門檻。醫療設備開發商與影像導航技術提供者之間的策略合作正逐漸成為建構貫穿整個手術流程（而不僅僅是單一產品）的統一解決方案的有效途徑。

為幫助產業領導者加強產品組合、最佳化營運、加速產品推廣以及應對政策和供應鏈逆風提供切實可行的策略建議。

產業領導者應推動一系列合作舉措，以平衡臨床差異化、供應鏈韌性和市場進入的有效性。首先，應優先投資於高品質的對比臨床證據和註冊登記，使其符合支付方要求和外科醫生決策標準，從而更清晰地展現手術對不同患者群體的益處。同時，應最佳化植入產品組合，重點關注模組化和互通性，以降低醫院和門診手術中心的庫存管理複雜性，並加速採用新型材料和固定方式。

透明的調查方法透過明確說明資料來源、訪談架構、分析方法、檢驗通訊協定和局限性，確保整合可靠的證據。

本研究途徑系統性地整合了同儕審查的臨床文獻、監管文件、操作指南和相關人員訪談，以建立可靠的證據基礎。主要資料收集包括對不同臨床環境下的臨床醫生、供應鏈和採購經理以及醫療設備商業化專家的訪談，以了解真實臨床實踐中的操作考慮和應用促進因素。次要研究則納入了醫療設備附加檔說明書、臨床實驗室註冊資料和技術白皮書，以檢驗臨床性能屬性和器械特性。

簡潔的結論整合了臨床、商業性和政策影響，並概述了相關人員將見解轉化為策略行動的優先事項。

總而言之，骶髂關節融合術正處於轉折點，醫療設備創新、手術流程改善和供應鏈趨勢的共同作用正在重塑臨床實踐和商業策略。在臨床方面，影像和導航技術的進步，以及材料和固定方法的創新，正在擴大微創手術的安全範圍，同時，在適當情況下，開放性手術仍然是一種選擇。在商業方面，需要製定周密的市場進入計劃，使產品設計與醫院、門診手術中心和專科診所的營運實際情況相符，從而應對產品類型、手術流程、醫療機構環境、手術入路、固定機制和銷售管道等多方面的市場細分。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 銷售管道分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：骶髂關節融合市場：依產品類型分類

  • 植入
    • PEEK籠
    • 鈦籠
  • 裝置

第9章：骶髂關節融合術市場：依手術方法分類

  • 微創
    • 在透視下
    • 導航支援
  • 開放性手術

第10章：骶髂關節融合市場：依手術方式分類

  • 側
  • 落後
  • 後外側

第11章：骶髂關節融合市場：以固定機制分類

  • 椎間融合裝置
  • 板式固定
  • 桿固定
  • 螺絲固定

第12章：骶髂關節融合市場：依銷售管道分類

  • 直銷
  • 銷售代理

第13章：骶髂關節融合市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第14章 骶髂關節融合市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：骶髂關節融合市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 骶髂關節融合市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國骶髂關節融合市場

第18章：中國骶髂關節融合手術市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alphatec Spine, Inc.
  • Aurora Spine Corporation
  • Camber Spine Technologies, LLC
  • Captiva Spine, Inc.
  • CoreLink, LLC
  • DePuy Synthes, Inc.
  • Foundation Fusion Solutions, LLC
  • Genesys Orthopedic Systems, LLC
  • Globus Medical, Inc.
  • Life Spine, Inc.
  • Medtronic plc
  • NuVasive, Inc.
  • Orthofix Medical Inc.
  • PainTEQ, LLC
  • RTI Surgical, Inc.
  • SeaSpine Holdings Corporation
  • SI-BONE, Inc.
  • SIGNUS Medizintechnik GmbH
  • Stryker Corporation
  • VGI Medical, LLC
  • Xtant Medical Holdings, Inc.
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-3A2E844FDC50

The Sacroiliac Joint Fusion Market was valued at USD 848.42 million in 2025 and is projected to grow to USD 942.86 million in 2026, with a CAGR of 12.29%, reaching USD 1,910.34 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 848.42 million
Estimated Year [2026] USD 942.86 million
Forecast Year [2032] USD 1,910.34 million
CAGR (%) 12.29%

Sacroiliac joint fusion landscape and clinical imperatives shaping device development patient pathways and provider decision-making in an evolving care environment

Sacroiliac joint fusion occupies an increasingly prominent place within the spine and pelvic care continuum as clinicians seek durable, minimally disruptive solutions for patients with refractory sacroiliac joint dysfunction. Patient selection has sharpened as diagnostic pathways integrate advanced imaging, targeted injections, and multidisciplinary evaluation, resulting in clearer indications for procedural intervention. Concurrently, device developers and proceduralists have focused on reducing tissue disruption and improving biomechanical stability while accounting for adjacent anatomy and long-term fusion biology.

This introduction frames the clinical landscape in which implants, instruments, procedural approaches, and facility types interact. Minimally invasive pathways are gaining traction alongside established open techniques, and approaches such as lateral and posterior access each offer distinct risk-benefit profiles that inform surgeon preference and device design. Meanwhile, differentiation between implant materials and fixation mechanisms reflects a balance of biomechanical performance, imaging compatibility, and surgeon familiarity. As hospitals, ambulatory surgical centers, and specialty clinics adapt to evolving reimbursement and care delivery models, decision-makers will increasingly evaluate devices not only on clinical outcomes but on integration into existing workflows, instrument sterilization practices, and inventory strategies.

Taken together, advancements in imaging guidance and navigation, coupled with iterative implant design, set the stage for continued refinement of patient pathways and adoption dynamics in the sacroiliac fusion arena.

Emerging technologies and care model disruptions driving rapid shifts in sacroiliac joint fusion procedures device design and clinical adoption patterns

The sacroiliac fusion landscape is undergoing transformative shifts driven by innovation in implant materials, intraoperative guidance, and procedural logistics. Advances in imaging and navigation have reduced dependence on fluoroscopic exposure for many teams, which in turn influences the procedural learning curve and operating room throughput. Navigation-assisted minimally invasive techniques enable more precise implant placement, potentially lowering complication rates and broadening the pool of patients eligible for intervention. At the same time, improvements in implant geometry and surface technology-coupled with expanded material choices-have encouraged designers to optimize for both initial fixation and long-term fusion biology.

Operationally, ambulatory surgical centers have embraced simplified instrumentation and streamlined procedural sets to support high-volume, low-cost delivery of care, while hospitals maintain a focus on complex cases and post-acute pathways. Distribution models have adapted accordingly: direct relationships between manufacturers and high-volume systems accelerate customization and service integration, whereas distributor-led channels remain critical for broad geographic reach and smaller facilities. Regulatory clarity and payer engagement around procedural coding and evidence requirements are also shaping product development priorities, incentivizing higher-quality clinical data and registry participation. Collectively, these shifts are recalibrating competitive dynamics and creating opportunities for entrants that can demonstrate clear value propositions across clinical outcomes, workflow efficiency, and total cost of care.

Assessment of how United States tariff changes in 2025 are reshaping supply chains procurement priorities pricing strategies and operational resilience across stakeholders

The suite of tariff changes enacted in the United States in 2025 has introduced new variables into procurement and supply chain strategies for medical device stakeholders. Manufacturers that source components or finished goods internationally have revisited supplier footprints to mitigate inbound duty exposure, accelerating conversations around nearshoring and dual-sourcing. These adjustments have implications for lead times and inventory policies, prompting hospitals, ambulatory surgical centers, and specialty clinics to evaluate buffer strategies and contractual flexibility to maintain continuity of care.

Procurement teams have increased scrutiny on landed cost calculations and total procurement cycle time, which has shifted negotiation dynamics with both direct manufacturers and distributors. For some suppliers, the tariff environment has catalyzed investments in domestic manufacturing capacity or in tariff engineering approaches to reclassify value-added processes, while others have absorbed duties to preserve competitive pricing and maintain market access. In practice, these strategic responses affect capital planning for facilities and can influence device selection where comparable clinical outcomes exist.

Importantly, policy uncertainty associated with tariff implementation timelines has elevated the strategic value of adaptive sourcing and scenario planning. Stakeholders that foster transparency across the supply chain and prioritize contractual resilience are positioning themselves to maintain stable access to critical implants, instruments, and procedural consumables despite evolving trade policy frameworks.

Segment-focused analysis revealing differentiated demand signals across product types procedure modalities end users approaches fixation mechanisms and distribution channels

A segmentation-focused lens reveals differentiated demand patterns and development priorities across product, procedure, end user, approach, fixation mechanism, and distribution dimensions. Based on product type, the field separates implants from instruments, with implants drawing particular attention to material choice; within implants, PEEK cage designs compete against titanium cage constructs, each offering distinct radiographic and biomechanical considerations that influence surgeon preference. Based on procedure type, the spectrum ranges from minimally invasive to open surgery modalities; minimally invasive options are further distinguished by fluoroscopy-guided workflows and navigation-assisted platforms, while open surgery pathways frequently rely on manual technique and established exposure strategies.

End user segmentation underscores the operational trade-offs among ambulatory surgical centers, hospitals, and specialty clinics, as each setting dictates different throughput, sterilization, and inventory constraints that affect product selection. Approach differentiation across lateral, posterior, and posterior lateral corridors drives implant geometry and instrumentation pathways to address unique anatomic vectors and access limitations. Fixation mechanism segmentation spotlights interbody devices, plate fixation, rod fixation, and screw fixation alternatives, which are chosen based on desired stability, fusion strategy, and surgeon comfort. Finally, distribution channel segmentation between direct and distributor routes shapes commercial engagement models, post-market support expectations, and product availability in diverse geographies. Synthesizing these segmentation axes provides a structured framework for prioritizing product development, clinical evidence generation, and go-to-market tactics tailored to distinct stakeholder needs.

Regional dynamics and patient demographics influencing adoption rates reimbursement pathways clinical infrastructure and commercialization strategies across global regions

Regional dynamics materially influence adoption choices, regulatory priorities, and commercialization pathways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established clinical pathways and a high concentration of advanced spine centers support rapid diffusion of minimally invasive techniques and advanced implants, while the structure of hospital networks and ambulatory surgical center growth shapes procurement cycles and purchasing negotiations. Moving to Europe, the Middle East & Africa corridor, heterogeneous regulatory frameworks and reimbursement systems create diverse adoption timelines; some markets favor centralized procurement and cost-effectiveness analyses, whereas others prioritize rapid access to novel devices through private hospital systems.

In the Asia-Pacific region, a combination of large patient volumes, expanding surgical capacity, and increasing local manufacturing capability fosters both demand and competitive pricing pressure. Across these regions, differences in imaging infrastructure, surgeon training models, and facility throughput drive preference for specific approaches and fixation mechanisms. Furthermore, cross-regional partnerships, regulatory harmonization efforts, and strategic manufacturing investments are shifting how companies deploy distribution channels and support clinical training, thereby shaping long-term commercial viability in each geography.

Competitive landscape insights highlighting strategic moves product innovation partnerships go-to-market approaches and capability gaps among device manufacturers and service providers

Company strategies in the sacroiliac fusion space have coalesced around three principal themes: differentiated clinical value, integrated service offerings, and operational scalability. Competitors that emphasize robust clinical evidence and clear procedural advantages have focused R&D on implant design optimization and instrumentation ergonomics to shorten operative time and reduce complication profiles. Others have pursued integrated systems that bundle navigation, implants, and service agreements to lower the barrier for adoption among surgical teams and facilities. Strategic partnerships between device developers and imaging or navigation technology providers have emerged as an effective route to create cohesive offerings that address a full procedural workflow rather than single-point products.

Commercially, some firms prioritize direct account management for large health systems to capture long-term formularies and clinical integration opportunities, while alternative players leverage distributor networks to reach a wider set of hospitals and specialty clinics. Post-market surveillance, registry participation, and real-world evidence collection are increasingly important differentiators, as payers and providers expect longitudinal outcomes data. Additionally, capability gaps remain in lifecycle support for devices-especially in training, instrument maintenance, and logistics-which opens opportunities for companies that can deliver comprehensive service models that reduce operational friction for customers.

Actionable strategic recommendations for industry leaders to strengthen portfolios optimize operations accelerate adoption and navigate policy and supply chain headwinds

Industry leaders should pursue a set of coordinated actions that balance clinical differentiation, supply chain resilience, and market access effectiveness. First, prioritize investment in high-quality comparative clinical evidence and registries that align with payer requirements and surgeon decision criteria, enabling clearer demonstrations of procedural benefit across patient cohorts. Simultaneously, optimize implant portfolios by focusing on modularity and cross-compatibility to reduce inventory complexity for hospitals and ambulatory centers while accelerating adoption of newer materials and fixation options.

From an operational perspective, develop flexible sourcing strategies that combine regional manufacturing, dual suppliers, and inventory optimization to mitigate tariff and transport volatility. Strengthen commercial models by offering tailored service bundles for large health systems through direct channels while leveraging distributor partnerships to maintain geographic coverage in smaller facilities. Invest in surgeon training programs and digital education platforms to shorten the learning curve for navigation-assisted and minimally invasive techniques, and align reimbursement teams early to shape coding and payment pathways. Finally, incorporate lifecycle service offerings-instrument maintenance, data analytics, and outcomes support-to deepen customer relationships and create recurring revenue streams that stabilize long-term growth.

Transparent research methodology outlining data sources interview frameworks analytical approaches validation protocols and limitations ensuring robust evidence synthesis

The research approach combined a structured synthesis of peer-reviewed clinical literature, regulatory documents, procedural guidance, and stakeholder interviews to produce a robust evidence base. Primary data collection included interviews with clinicians across diverse practice settings, supply chain and procurement leaders, and device commercialization experts to capture real-world operational considerations and adoption drivers. Secondary research incorporated device labeling, clinical trial registries, and technical white papers to validate clinical performance attributes and device characteristics.

Analytical steps involved cross-referencing clinical outcomes with procedural approaches and device attributes to identify alignment and gaps across segmentation axes. Qualitative insights were triangulated with supply chain and policy analyses to assess the practical implications of trade and procurement dynamics. Validation processes included follow-up conversations with selected respondents and external expert review to ensure interpretive coherence. Limitations of the methodology include variation in regional data availability and the evolving nature of device approvals and procedural reimbursement pathways; these were mitigated by emphasizing trends supported by multiple independent sources and explicit documentation of assumptions underlying segmentation analyses.

Concise conclusion synthesizing clinical, commercial, and policy implications and outlining priorities for stakeholders to translate insights into strategic action

In summary, sacroiliac joint fusion is at an inflection point where device innovation, procedural refinement, and supply chain dynamics are collectively reshaping clinical practice and commercial strategies. Clinically, advances in imaging and navigation coupled with material and fixation innovations are expanding the safe application of minimally invasive techniques while preserving options for open surgery where appropriate. Commercially, segmentation across product types, procedural modalities, facility settings, approaches, fixation mechanisms, and distribution channels requires nuanced go-to-market planning that aligns product design with the operational realities of hospitals, ambulatory surgical centers, and specialty clinics.

Policy and trade developments have underscored the need for resilient sourcing and adaptable procurement models. Companies that combine compelling clinical evidence, streamlined instrumentation, and comprehensive lifecycle services will be best positioned to capture long-term clinical adoption and institutional partnerships. For stakeholders across the ecosystem, the emphasis should be on translating evidence into practice through training, integrated workflows, and value-based conversations with payers and providers to ensure patient access and procedural sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sacroiliac Joint Fusion Market, by Product Type

  • 8.1. Implants
    • 8.1.1. PEEK Cage
    • 8.1.2. Titanium Cage
  • 8.2. Instruments

9. Sacroiliac Joint Fusion Market, by Procedure Type

  • 9.1. Minimally Invasive
    • 9.1.1. Fluoroscopy Guided
    • 9.1.2. Navigation Assisted
  • 9.2. Open Surgery

10. Sacroiliac Joint Fusion Market, by Approach

  • 10.1. Lateral
  • 10.2. Posterior
  • 10.3. Posterior Lateral

11. Sacroiliac Joint Fusion Market, by Fixation Mechanism

  • 11.1. Interbody Devices
  • 11.2. Plate Fixation
  • 11.3. Rod Fixation
  • 11.4. Screw Fixation

12. Sacroiliac Joint Fusion Market, by Distribution Channel

  • 12.1. Direct
  • 12.2. Distributor

13. Sacroiliac Joint Fusion Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Hospitals
  • 13.3. Specialty Clinics

14. Sacroiliac Joint Fusion Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Sacroiliac Joint Fusion Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Sacroiliac Joint Fusion Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Sacroiliac Joint Fusion Market

18. China Sacroiliac Joint Fusion Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Alphatec Spine, Inc.
  • 19.6. Aurora Spine Corporation
  • 19.7. Camber Spine Technologies, LLC
  • 19.8. Captiva Spine, Inc.
  • 19.9. CoreLink, LLC
  • 19.10. DePuy Synthes, Inc.
  • 19.11. Foundation Fusion Solutions, LLC
  • 19.12. Genesys Orthopedic Systems, LLC
  • 19.13. Globus Medical, Inc.
  • 19.14. Life Spine, Inc.
  • 19.15. Medtronic plc
  • 19.16. NuVasive, Inc.
  • 19.17. Orthofix Medical Inc.
  • 19.18. PainTEQ, LLC
  • 19.19. RTI Surgical, Inc.
  • 19.20. SeaSpine Holdings Corporation
  • 19.21. SI-BONE, Inc.
  • 19.22. SIGNUS Medizintechnik GmbH
  • 19.23. Stryker Corporation
  • 19.24. VGI Medical, LLC
  • 19.25. Xtant Medical Holdings, Inc.
  • 19.26. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SACROILIAC JOINT FUSION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SACROILIAC JOINT FUSION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA SACROILIAC JOINT FUSION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PEEK CAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PEEK CAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PEEK CAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY TITANIUM CAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY TITANIUM CAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY TITANIUM CAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY FLUOROSCOPY GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY FLUOROSCOPY GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY FLUOROSCOPY GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY NAVIGATION ASSISTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY NAVIGATION ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY NAVIGATION ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY LATERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY LATERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY LATERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY POSTERIOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY POSTERIOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY POSTERIOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY POSTERIOR LATERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY POSTERIOR LATERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY POSTERIOR LATERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY INTERBODY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY INTERBODY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY INTERBODY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PLATE FIXATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PLATE FIXATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY PLATE FIXATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY ROD FIXATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY ROD FIXATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY ROD FIXATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY SCREW FIXATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY SCREW FIXATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY SCREW FIXATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DIRECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DIRECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DIRECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 159. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 160. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GCC SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 183. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 186. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 187. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. G7 SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 192. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 195. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 196. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. NATO SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL SACROILIAC JOINT FUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA SACROILIAC JOINT FUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY FIXATION MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA SACROILIAC JOINT FUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)